A Phase 3 interventional study of Atorvastatin 10 mg and Ezetimibe 10 mg/simvastatin 20 mg in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 6th largest by enrollment of the 75 interventional ones that give a count, is one of 8 that started in 2007, is one of 31 in phase 3, and was the 23rd registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,289 is above the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 75 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 77 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 8th largest by enrollment of the 81 interventional ones that give a count, is one of 13 that started in 2007, is one of 58 in phase 3, and was the 41st registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, from their registry updates:
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus atorvastatin in elderly patients with high cholesterol at high or moderately high risk for coronary heart disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Each patient will receive 1 active treatment dose \& 2 Placebo (Pbo) doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
Drug: Atorvastatin 10 mg
Each patient will receive 1 active treatment dose \& 2 Pbo doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
Drug: Ezetimibe 10 mg/simvastatin 20 mg
Each patient will receive 1 active treatment dose \& 2 Pbo doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
Drug: Atorvastatin 20 mg
Each patient will receive 1 active treatment dose \& 2 Pbo doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
Drug: Ezetimibe 10 mg/simvastatin 40 mg
Each patient will receive 1 active treatment dose \& 2 Pbo doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
Drug: Atorvastatin 40 mg
Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Drug page: Ezetimibe
Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Drug page: Ezetimibe
Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12
Time frame: Baseline and 12 weeks
Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12
Time frame: 12 weeks
Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12
Patients with AVD Who Achieved LDL-C \<70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.
Time frame: 12 Weeks
Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12
Time frame: 12 Weeks
Percentage of Patients With High Risk for CHD Who Achieved LDL-C <70 mg/dL at Week 12
Risk was assessed utilizing a history of established CHD or CHD risk equivalent and Framingham Risk scoring.
Time frame: 12 Weeks
Percentage of Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12
Patients with AVD Who Achieved LDL-C \<70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.
Time frame: 12 Weeks
Phase III First Patient In 08-Nov-2007; Last Patient Last Visit 23-Mar-2009 Eligible patients include drug-naïve patients or patients rendered naïve with the appropriate prior washout at moderately high or high risk for coronary heart disease 65 years and older.
| Milestone | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Started | 257 | 259 | 259 | 257 | 257 |
| Completed | 240 | 233 | 241 | 235 | 241 |
| Not completed | 17 | 26 | 18 | 22 | 16 |
| Withdrew: Adverse event | 6 | 8 | 3 | 8 | 6 |
| Withdrew: Lost to follow-up | 1 | 3 | 3 | 2 | 1 |
| Withdrew: Physician decision | 3 | 2 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 2 | 2 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 11 | 10 | 10 | 8 |
| Percent change in LDL-C | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12 | -39.5 (-41.4 to -37.5) | -54.2 (-56.1 to -52.2) | -46.6 (-48.6 to -44.7) | -59.1 (-61.0 to -57.1) | -50.8 (-52.8 to -48.9) |
| Percent of Patients | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12 | 9.9 ± 1.92 | 51.3 ± 3.28 | 26.1 ± 2.85 | 68.2 ± 3.03 | 38.1 ± 3.14 |
Patients with AVD Who Achieved LDL-C \<70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.
| Percent of Patients | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12 | 45.0 ± 3.20 | 69.0 ± 3.04 | 61.3 ± 3.16 | 82.1 ± 2.50 | 69.9 ± 2.97 |
| Percent of Patients | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12 | 58.7 ± 3.17 | 83.6 ± 2.43 | 76.9 ± 2.73 | 90.3 ± 1.93 | 79.5 ± 2.61 |
Risk was assessed utilizing a history of established CHD or CHD risk equivalent and Framingham Risk scoring.
| Percent of Patients | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percentage of Patients With High Risk for CHD Who Achieved LDL-C <70 mg/dL at Week 12 | 10.9 ± 2.65 | 54.3 ± 4.24 | 28.9 ± 4.01 | 69.2 ± 4.05 | 38.2 ± 4.17 |
Patients with AVD Who Achieved LDL-C \<70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.
| Percent of Patients | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percentage of Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12 | 10.0 ± 3.59 | 44.4 ± 5.52 | 31.6 ± 5.23 | 65.8 ± 5.34 | 44.4 ± 5.86 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin 10 mg | — | 4/257 (1.6%) | 26/257 (10.1%) |
| Ezetimibe 10 mg/Simvastatin 20 mg | — | 8/256 (3.1%) | 32/256 (12.5%) |
| Atorvastatin 20 mg | — | 3/258 (1.2%) | 26/258 (10.1%) |
| Ezetimibe 10 mg/Simvastatin 40 mg | — | 3/257 (1.2%) | 32/257 (12.5%) |
| Atorvastatin 40 mg | — | 5/256 (2%) | 30/256 (11.7%) |
| Event | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorvastatin 40 mg |
|---|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/257 | 2/256 | 0/258 | 0/257 | 0/256 |
| Myocardial infarctionCardiac disorders | 0/257 | 0/256 | 0/258 | 2/257 | 0/256 |
| AV dissociationCardiac disorders | 0/257 | 1/256 | 0/258 | 0/257 | 0/256 |
| Abdominal painGastrointestinal disorders | 0/257 | 0/256 | 0/258 | 0/257 | 1/256 |
| Colitis ischaemicGastrointestinal disorders | 0/257 | 1/256 | 0/258 | 0/257 | 0/256 |
| Diverticulum intestinalGastrointestinal disorders | 0/257 | 1/256 | 0/258 | 0/257 | 0/256 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/257 | 1/256 | 0/258 | 0/257 | 0/256 |
| Oedema peripheralGeneral disorders | 0/257 | 0/256 | 0/258 | 0/257 | 1/256 |
| Urinary tract infectionInfections and infestations | 0/257 | 0/256 | 0/258 | 0/257 | 1/256 |
| Femur fractureInjury, poisoning and procedural complications | 0/257 | 0/256 | 0/258 | 0/257 | 1/256 |
| Event | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorvastatin 40 mg |
|---|---|---|---|---|---|
| DizzinessNervous system disorders | 2/257 | 6/256 | 0/258 | 2/257 | 3/256 |
| ConstipationGastrointestinal disorders | 3/257 | 0/256 | 0/258 | 4/257 | 5/256 |
| NasopharyngitisInfections and infestations | 2/257 | 5/256 | 4/258 | 3/257 | 2/256 |
| HeadacheNervous system disorders | 1/257 | 5/256 | 3/258 | 3/257 | 2/256 |
| Back painMusculoskeletal and connective tissue disorders | 5/257 | 2/256 | 3/258 | 4/257 | 4/256 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/257 | 3/256 | 3/258 | 2/257 | 3/256 |
| BronchitisInfections and infestations | 1/257 | 2/256 | 4/258 | 4/257 | 4/256 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/257 | 4/256 | 4/258 | 1/257 | 1/256 |
| DiarrhoeaGastrointestinal disorders | 3/257 | 1/256 | 1/258 | 4/257 | 3/256 |
| Aspartate aminotransferase increasedInvestigations | 0/257 | 2/256 | 0/258 | 4/257 | 3/256 |
| Age, Continuous(years) | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 72.1 (65 to 94) | 71.8 (65 to 95) | 71.7 (65 to 90) | 72.2 (65 to 96) | 72.1 (65 to 88) | 72.0 (65 to 96) |
| Sex: Female, Male(Participants) | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg | Total |
|---|---|---|---|---|---|---|
| Female | 172 | 146 | 175 | 153 | 163 | 809 |
| Male | 85 | 113 | 84 | 104 | 94 | 480 |
| Race/Ethnicity, Customized(participants) | Atorvastatin 10 mg | Ezetimibe 10 mg/Simvastatin 20 mg | Atorvastatin 20 mg | Ezetimibe 10 mg/Simvastatin 40 mg | Atorva 40 mg | Total |
|---|---|---|---|---|---|---|
| Asian | 10 | 6 | 12 | 8 | 10 | 46 |
| Black | 2 | 2 | 8 | 6 | 9 | 27 |
| Other | 21 | 27 | 30 | 29 | 28 | 135 |
| White | 224 | 224 | 209 | 214 | 210 | 1081 |
No study locations are listed for this record.
Plan to share: No
The record gives a start of Nov 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atorvastatin · Ezetimibe